Patent ID: 7820817

Claim:
A compound of formula (IV): or a pharmaceutically acceptable salt thereof, wherein A IV is adamantanyl, adamantanylmethyl, or Bond r is a single or double bond; Each X 1 is independently selected from CH 2 , CH 2 —CH 2 , or NR 400 , Each W 1 is independently selected from a bond or —(CH 2 ) i —, Each R 5 is independently a phenyl, indenyl, naphthalenyl, tetrahydronaphthyl, furyl, thiophenyl, pyrrolyl, oxazolyl, thazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, isoquinolinyl, cycloaliphatic, or heterocyclic ring, each optionally including 1 to 3 R 100 substituents; Each R 6 is independently H or aliphatic optionally substituted with R 7 ; Each R 7 is independently a phenyl, indenyl, naphthalenyl, tetrahydronaphthyl, furyl, thiophenyl, pyrrolyl, oxazolyl, thazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, isoquinolinyl, cycloaliphatic, or heterocyclic ring, each optionally substituted with up to 2 substituents independently selected from H, (C 1 -C 6 )-straight or branched alkyl, (C 2 -C 6 ) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or —(CH 2 ) n —Z; Each Z is independently selected from halo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —S-aliphatic, —S(O)-aliphatic, —S(O) 2 -aliphatic, —COOH, —C(O)O(-aliphatic), or —O-aliphatic; G is N; V is Each Z2 is independently a carbon atom; Each Z4 and Z6 is independently —C(H)═ or —C(R 100 )═; Each Z1, Z3, and Z5 is independently —N═, —C(H)═, or —C(R 200 )═, provided a) that one of Z1, Z3, and Z5 is —N═; d) when Z4 or Z6 is —C(R 100 )═, that (i) one of Z1 and Z3 is —C(R 100 )═, (ii) Z5 is —C(R 200 )═, or (iii) both Z4 and Z6 are —C(R 100 )═; Each R 100 is independently is —((C 1 -C 4 )aliphatic) p -Y2; Y2 is halo, —CN, —NO 2 , —CF 3 , —OCF 3 , —SR 600 , —S(O)R 600 , —S(O) 2 R 600 , —S(O) 2 NR 600 , —COOR 600 , —C(O)N(R 600 ) 2 , or —OR 600 ; or Each R 200 is independently R 100 or phenyl optionally substituted with 1-3 halo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH; Each R 400 is independently OR 5 , OR 6 , S(O)R 6 , S(O)R 5 , S(O) 2 R 6 , S(O) 2 R 5 , S(O) 2 N(R 6 ) 2 , S(O) 2 N(R 5 ) 2 , S(O) 2 NR 5 R 6 , S(O) 3 R 6 , S(O) 3 R 5 , C(O)R 5 , C(O)OR 5 , C(O)R 6 , C(O)OR 6 , C(O)N(R 6 ) 2 , C(O)N(R 5 ) 2 , C(O)N(R 5 R 6 ), C(O)N(OR 6 )R 6 , C(O)N(OR 5 )R 6 , C(O)N(OR 6 )R 5 , C(O)N(OR 5 )R 5 , C(NOR 6 )R 6 , C(NOR 6 )R 5 , C(NOR 5 )R 6 , and C(NOR 5 )R 5 ; Each R 600 is independently H or aliphatic optionally substituted with 1-3 substituents selected from halo, —CN, —NO 2 , —CF 3 , —OCF 3 , or —OH; Each x is 1; Each i is 0, 1 2, or 3; Each m is independently 1 or 2; Each p is independently 0 or 1; and further provided that when G is N and A IV is azabicyclo[3.2.1]octane-8-carboxylic acid t-butyl ester, then V is not-pyridine-2-yl-5-carboxylic acid.